Investigating The Impact Of Coincident Modulation Of Adenosine And Glutamate Receptors On Neuronal Activity – Implications For CNS Drug Discovery
Funder
National Health and Medical Research Council
Funding Amount
$648,447.00
Summary
Dementia in particular Alzheimer's disease, is one of the leading causes of death. There remains a need for new drugs to treat both symptoms and disease progression. Two receptors in the brain, the adenosine A1 (A1AR) and metabotropic glutamate 5 (mGlu5) are suggested to be promising new drug targets for dementia. In order to better develop drugs that target these receptors, we will develop a better understanding of activity of these receptors under conditions of health and disease.
Interactions Between Developmental NMDA Receptor Dysfunction, Genetic Vulnerability And Early-life Stress In Schizophrenia: Studies Of Dysbindin Mutant Mice And Living Individuals At High Risk Of Schizophrenia
Funder
National Health and Medical Research Council
Funding Amount
$347,457.00
Summary
This project will investigate two key pathways implicated in schizophrenia: glutamatergic (excitatory) neurotransmission and stress signalling. We will study how glutamatergic deficits emerge across postnatal development, in the presence or absence of early-life stress, in a schizophrenia-relevant mouse model, and investigate the interactions between stress and glutamatergic deficits in neuroepithelial cells from living individuals at high risk of schizophrenia.
Anxiety and addiction are disorders with high co-morbidity that present a major worldwide public health concern. Treatment in both cases often involves an approach called extinction which helps to reduce the relapsing nature of these disorders. This grant is designed to examine the role of a specific protein in addiction and anxiety, by virtue of its involvement in the process of extinction.
Factors Predisposing To Post Operative Epilepsy In Patients With Supratentorial Gliomas
Funder
National Health and Medical Research Council
Funding Amount
$66,550.00
Summary
Tumour associated epilepsy, a common, disabling problem for patients with brain tumours called gliomas is often refractory to medical treatment and the mechanisms by which gliomas cause seizures are unknown. This is the first extensive observational study looking at molecular factors within the brain such as Hyperpolarization ion channels, glutamate uptake receptors and ADAM22 genes that may help determine which patients with gliomas will develop epilepsy and which ones will not.
Biased Allosteric Modulators Of Metabotropic Glutamate Receptors: Novel Therapeutic Targets For CNS Disorders
Funder
National Health and Medical Research Council
Funding Amount
$611,534.00
Summary
Metabotropic glutamate receptor 5 (mGlu5) is a major therapeutic target for depression and schizophrenia. The proposed studies will improve our understanding of how drug-like chemicals interact with mGlu5 and therefore change the activity of these receptors and in turn the activity of brain cells leading to therapeutic effectiveness. The research undertaken in this program will allow us to be smarter in developing new mGlu5 drugs that are both effective and have minimal side effects.
Regulation Of Glutamate Receptor Trafficking By The Calcium- And Lipid-binding Protein, Copine-6
Funder
National Health and Medical Research Council
Funding Amount
$548,690.00
Summary
Abnormal levels of cell surface receptors in neurons can lead to a variety of debilitating neurological disorders and neurodegenerative diseases. These levels are tightly regulated through the orchestrated movements of receptors from inside the neuron to the cell surface. In this project we will examine how the transport of cell surface receptors is regulated by an intracellular signalling molecule, called copine, which is important in both epilepsy and Alzheimer’s disease.